Provided by Tiger Trade Technology Pte. Ltd.

Oric Pharmaceuticals Inc.

12.07
-0.4300-3.44%
Volume:1.03M
Turnover:12.58M
Market Cap:1.25B
PE:-8.93
High:12.79
Open:12.64
Low:12.01
Close:12.50
52wk High:14.93
52wk Low:7.23
Shares:103.52M
Float Shares:88.69M
Volume Ratio:0.84
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3513
EPS(LYR):-1.4747
ROE:-39.80%
ROA:-25.97%
PB:3.28
PE(LYR):-8.18

Loading ...

ORIC Pharmaceuticals to Launch Phase 3 Trial of Prostate Cancer Drug Candidate, Shares Falter

MT Newswires Live
·
Apr 01

Oric Pharmaceuticals: Continue to Evaluate Rinzimetostat in Additional Indications in Prostate Cancer and Beyond

THOMSON REUTERS
·
Apr 01

Oric Pharmaceuticals: Expect First Phase 3 Trial, Himalayas-1, in Patients With Mcrpc Previously Treated With Abiraterone, to Initiate in H1 2026

THOMSON REUTERS
·
Apr 01

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

GlobeNewswire
·
Apr 01

Oric Pharmaceuticals to present Phase 1b rinzimetostat combination dose-optimization data in mCRPC; March 31 conference call set for 4:30pm ET

Reuters
·
Mar 27

Oric® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1B Trial of Rinzimetostat in Patients With Mcrpc

THOMSON REUTERS
·
Mar 27

Oric Pharmaceuticals to present rinzimetostat preclinical data at AACR Annual Meeting

Reuters
·
Mar 18

ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire
·
Mar 18

A Look At ORIC Pharmaceuticals (ORIC) Valuation After Competitor Tazverik Withdrawal And Analyst Support

Simply Wall St.
·
Mar 15

Oric Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 13

Constructive Buy Thesis on ORIC Driven by Differentiated PRC2 Biology and Manageable Safety Profile for Rinzimetostat

TIPRANKS
·
Mar 10

Cantor says Oric move down on tazemetostat withdrawal an ‘over-reaction’

TIPRANKS
·
Mar 10

Oric Pharmaceuticals falls after peer Ipsen voluntarily withdraws Tazverik

TIPRANKS
·
Mar 09